1. Introduction {#sec1}
===============

The infection of the newly emerged severe acute respiratory syndrome coronavirus (SARS-CoV) is characterized by acute flu-like symptoms that progress to acute lung injury or acute respiratory distress syndrome with over 10% of mortality [@bib1]. To date there are no universally recommended therapy for the disease. Many scientists are now making efforts to develop effective drugs against SARS. The combination therapy of corticosteroid with lopinavir, ribavirin and ritonavir can improve clinical response and reduce mortality rates apparently [@bib2], [@bib3]. Cinatl et al. [@bib4] found that ribavirin, azauridine, pyrazofurin and glycyrrhizin are active against SARS-CoV. Barnard et al. [@bib5] reported that calpain inhibitors and β-[d]{.smallcaps}-N^4^-hydroxycytidine exhibit inhibitory effects on SARS-CoV.

Structure-based drug design focuses on two important approaches: one is receptor-based docking technique, another is pharmacophore-based virtual screening technique. A pharmacophore is the 3D arrangement of atoms or functional groups essential for the compound to bind to a specific receptor [@bib6]. The power of a pharmacophore model is to discover new leads by using 3D database pharmacophore searching and guide chemists to synthesize new compounds [@bib7]. Such a pharmacophore-based method has been successfully applied to many drug development programs [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18]. The main proteinase of SARS-CoV plays an important role in virus replication and is the primary target for drugs. The aim of this study is to develop 3D pharmacophore models for SARS-CoV main proteinase and expect to provide useful knowledge for anti-SARS drug design.

2. Material and methods {#sec2}
=======================

There are two methods to derive a reasonable pharmacophore model. One is from the crystal structure of protein--ligand complex, another is based on molecular modeling of enzyme with its potential inhibitors. Here we used the experimental structure of SARS-CoV main proteinase complexed with its peptide inhibitor CMK (PDB ID 1UK4) [@bib19] and the predicted structures of SARS-CoV main proteinase with six drugs/compounds [@bib20] for establishing pharmacophore models. The structures of CMK peptide and six compounds are shown in [Fig. 1](#fig1){ref-type="fig"} .Fig. 1The peptide and compounds used for pharmacophore generation.

The POCKET module in LigBuilder program [@bib21] was employed to obtain the pharmacophore models of SARS-CoV main proteinase. This approach was successfully applied to the identification of novel inhibitors for alanine racemase [@bib22]. The proposed pharmacophore model is a binding-site-derived pharmacophore model, which includes the following pharmacophore features of ligands binding to the enzyme's active site: a positively charged nitrogen atom (ammonium cation) to represent a hydrogen bond donor (HBD), a negatively charged oxygen atom (as in a carboxyl group) to represent a hydrogen bond acceptor (HBA), and a carbon atom (methane) to represent a hydrophobic center (HPC). A pharmacophore model is generated for each protein--ligand complex.

3. Results and discussion {#sec3}
=========================

Using CMK peptide and six compounds in [Fig. 1](#fig1){ref-type="fig"}, we generated a set of seven eight-point pharmacophore models for SARS-CoV main proteinase, which is listed in [Table 1](#tbl1){ref-type="table"} . These hypotheses exhibit different features due to the diversities of the compounds involved. Based on these models, we extracted a common four-point pharmacophore distance pattern shown in [Fig. 2](#fig2){ref-type="fig"} , P1 is HBA, HBD and HPC, P2 is HBA and HPC, P3 is HBA and HBD, P4 is HBA and HBD. Such a pharmacophore distance pattern was subsequently used for the 3D database search.Table 1The eight-point pharmacophore models obtained by LigBuilder from seven peptide and compoundsPharmacophorePeptide/compoundsFeatures1CMK peptideHBD HBD HPC HBD HPC HBD HPC HBA2LopinavirHBA HBD HBA HBD HBA HBA HBA HBA3RitonavirHPC HPC HBD HBD HBD HBA HBD HBA4NiclosamideHBA HBD HBA HBA HBA HBD HPC HBA5PromazineHBA HBD HBA HPC HBA HBA HBA HBA6PNUHBA HPC HBA HBD HBD HBA HBA HBA7UC2HPC HBD HBD HBA HBD HPC HPC HBA[^1]Fig. 2Four-point pharmacophore distance pattern for SARS-CoV main proteinase. Here, P1 is HBA, HBD and HPC, P2 is HBA and HPC, P3 is HBA and HBD, P4 is HBA and HBD.

The pharmacophore searching in 3D database was conducted in the 3D NCI database, which has 250, 251 open structures ready for searching. [Table 2](#tbl2){ref-type="table"} summarizes the results for similarity search of above-mentioned four-point pharmacophore model with constraints: (1) the distance ranges for P1P2, P1P3, P2P3, P1P4, P2P4 and P3P4 ([Fig. 2](#fig2){ref-type="fig"}) are 2--3, 2--3, 1.5--2.5, 5--6, 3--4 and 3--4 Å, respectively; (2) the compound is drug; (3) the antiviral probability is over 70%; (4) the compounds labeled as "No Name" is not included. After review of these hitlists, 30 drugs were selected for further analysis, their chemical structures and bioactivities (documented in anti-HIV and anti-opportunistic infection chemical compound database, which contains approximately 100,000 compounds, <http://www.apps1.niaid.nih.gov/struct_search/an/an_search.htm>) are shown in [Fig. 3](#fig3){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"} , respectively. It is noted that almost all drugs exhibited anti-HIV activity, and some of them have activities against *Mycobacterium tuberculosis* (puromycin), influenza virus (5-bromo-2′-deoxycytidine), hepatitis virus (dideoxyguanosine, 2′,3′-dideoxycytidine and ribavirin), dengue virus (azauridine and ribavirin), rhinovirus and poliovirus (ribavirin). This should be very meaningful in consideration of the following facts: (1) there are some links between SARS-CoV and HIV and HBV [@bib23], [@bib24], [@bib25]; (2) similar structure patterns exist in SARS-CoV main proteinase with rhinovirus 3c protease, poliovirus 3c proteinase, HAV 3c protease, HCV Ns3 protease and dengue virus Ns3 protease [@bib26]; (3) SARS-CoV has clinically similar symptoms with influenza virus/*M. tuberculosis*, such as fever, cough, pains, pneumonia and death [@bib27].Table 2Summary of NCI database search by four-point pharmacophoresPharmacophore features in Fig. 2HitsP1P2P3P4HBDHBAHBDHBD987HBAHBAHBAHBA794HPCHBAHBAHBD286HPCHPCHBAHBD305HPCHBAHBDHBD298HBAHBAHBDHBD881HBAHBAHBAHBD895[^2]Fig. 3Chemical structures of 30 drugs obtained by four-point pharmacophore search in NCI 3D database.Table 3Thirty drugs obtained by four-point pharmacophore search in NCI 3D databaseNameNSC numberFormulaBioactivity documented in HIV/OI therapeutics database (<http://www.apps1.niaid.nih.gov/struct_search/an/an_search.htm>)PD-ADI218321C~11~H~16~N~4~O~4~HIVCoformycin277817C~11~H~16~N~4~O~5~HIVZidovudine602670C~10~H~13~N~5~O~4~HIV, HSV, human cytomegalovirus, vaccinia virus, cowpox virusVira-A404241C~10~H~13~N~5~O~4~HIV, HSV, human cytomegalovirus, varicella-zoster virus, vaccinia virus, cowpox virusAngustmycin C53104C~11~H~15~N~5~O~5~ARA-AMP259272C~10~H~14~N~5~O~7~PHIV, HSV, vaccinia virusCordycepin63984C~10~H~13~N~5~O~3~HIVTriciribine154020C~13~H~16~N~6~O~4~HIV, human cytomegalovirus, HSV5-AZCR102816C~8~H~12~N~4~O~5~HIVPuromycin3055C~22~H~29~N~7~O~5~HIV, *M. tuberculosis*CHETOMIN289491C~31~H~30~N~6~O~6~S~4~HIVVengicide99843C~12~H~13~N~5~O~4~Human cytomegalovirusSpongothymidin68929C~10~H~14~N~2~O~6~HIV, HSV, varicella-zoster virusArauridine68928C~9~H~12~N~2~O~6~P-Ara-C135962C~25~H~43~N~3~O~6~HIVPyrazofurin143095C~9~H~13~N~3~O~6~HIV, vaccinia virus, West Nile virusThymidin21548C~10~H~14~N~2~O~5~HIV, varicella-zoster virusRadibud38297C~9~H~11~BrN~2~O~5~Alexan63878C~9~H~13~N~3~O~5~HIV, HSV, human cytomegalovirus, varicella-zoster virus, measles virusFloxuridin27640C~9~H~11~FN~2~O~5~HIV, HSV, vaccinia virusGemcitabine613327C~9~H~12~ClF~2~N~3~O~4~HIV, cowpox virus, vaccinia virusDideoxyguanosine619072C~10~H~13~N~5~O~3~HIV, HBV2′,3′-Dideoxycytidine606170C~9~H~13~N~3~O~3~HIV, HBV5-Bromo-2′-deoxycytidine61765C~9~H~12~BrN~3~O~4~HSVRibavirin163039C~8~H~12~N~4~O~5~HIV, HSV, HCV, influenza virus, dengue virus, measles virus, respiratory syncytial virus, rhinovirus, polio virus, vaccinia virus, cowpox virusAzauridine32074C~8~H~11~N~3~O~6~West Nile virus, cowpox virus, vaccinia virus, dengue virus, Japanese encephalitis virus, Yellow fever virusFialuridine678514C~9~H~10~FIN~2~O~5~Cowpox virus, vaccinia virus, HSV, varicella-zoster virusEmanil39661C~9~H~11~IN~2~O~5~HIV, HSV, cowpox virus, vaccinia virus, varicella-zoster virusTubercidin56408C~11~H~14~N~4~O~4~HIV, vaccinia virus, human cytomegalovirusViroptic75520C~10~H~11~F~3~N~2~O~5~HSV, cowpox virus, vaccinia virus

Indeed, among the 30 drugs are six compounds that already exhibited anti-SARS-CoV activity experimentally: azauridine, pyrazofurin, ribavirin, 2′,3′-dideoxycytidine, dideoxyguanosine, and 5-bromo-2′-deoxycytidine [@bib4], [@bib5]. This shows that our pharmacophore model can lead to the discovery of potent anti-SARS-CoV inhibitors or at least provide some useful clues. [Fig. 4](#fig4){ref-type="fig"} shows the mappings of the six compounds into the four-point pharmacophore model, which are mapped to 1--3 HBA, 1--2 HBD and 0--1 HPC. In addition, most of the remaining compounds have remarkable similarities with one of the above six compounds, for example, azauridine with 5-AZCR, alexan, arauridine and spongothymidin; 5-bromo-2′-deoxycytidine with emanil, fialuridine, floxuridin, radibud, thymidin and viroptic; dideoxyguanosine with angustmycin C, cordycepin, tubercidin, vengicide and vira-A. The superpositions for these compounds are shown in [Fig. 5](#fig5){ref-type="fig"} . In summary, our results indicate that the existing 30 drugs identified by our pharmacophore model could be potential inhibitors against SARS-CoV, or at least good lead compounds for anti-SARS-CoV drug design.Fig. 4The mappings of six compounds that experimentally exhibited anti-SARS-CoV activity into the four-point pharmacophore model: (A) azauridine, (B) 5-bromo-2′-deoxycytidine, (C) dideoxycytidine, (D) dideoxyguanosine, (E) pyrazofurin, (F) ribavirin.Fig. 5Superpositions of anti-SARS-CoV compounds with other compounds. (A) azauridine with 5-AZCR, alexan, arauridine and spongothymidin; (B) 5-bromo-2′-deoxycytidine with email, fialuridine, floxuridin, radibud, thymidin and viroptic; (C) dideoxyguanosine with angustmycin C, cordycepin, tubercidin, vengicide and vira-A.
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[^1]: HBA = hydrogen bond acceptor, HBD = hydrogen bond donor, HPC = hydrophobic center.

[^2]: HBA = hydrogen bond acceptor, HBD = hydrogen bond donor, HPC = hydrophobic center.
